Harold H. Shlevin - 26 Jun 2026 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
30 Jun 2026, 19:24:12 UTC
Prior SEC filing
21 Jan 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Jack W. Callicutt, by power of attorney

Key filing fact

Harold H. Shlevin filed Form 4 for GALECTIN THERAPEUTICS INC (GALT) on 30 Jun 2026.

Key facts

  • This page summarizes Harold H. Shlevin's Form 4 filing for GALECTIN THERAPEUTICS INC (GALT).
  • 6 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 30 Jun 2026, 19:24.

Change

  • Previous filing in this sequence was filed on 21 Jan 2026.
  • Current net transaction value: -$150,891.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001557082 Primary reporting owner

Shlevin Harold H.

Relationship
Director
Address
C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS
Signature
Jack W. Callicutt, by power of attorney
Signature date
30 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GALT transaction

Common Stock

Options Exercise

Transaction value
Shares
+7,732
Change %
+119%
Price
$1.23*
Shares after
14,232
Date
26 Jun 2026
Ownership
Direct
Footnotes
F1
GALT transaction

Common Stock

Sale

Transaction value
$38,660
Shares
-7,732
Change %
-54%
Price
$5.00
Shares after
6,500
Date
26 Jun 2026
Ownership
Direct
Footnotes
F1, F2
GALT transaction

Common Stock

Options Exercise

Transaction value
Shares
+22,268
Change %
+343%
Price
$1.23*
Shares after
28,768
Date
29 Jun 2026
Ownership
Direct
Footnotes
F1
GALT transaction

Common Stock

Sale

Transaction value
$112,231
Shares
-22,268
Change %
-77%
Price
$5.04
Shares after
6,500
Date
29 Jun 2026
Ownership
Direct
Footnotes
F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GALT transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-7,732
Change %
-13%
Price
$0.000000*
Shares after
52,268
Date
26 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,732
Exercise price
$1.23
Footnotes
F1, F3
GALT transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-22,268
Change %
-43%
Price
$0.000000*
Shares after
30,000
Date
29 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
22,268
Exercise price
$1.23
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025

Footnote F2

The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Footnote F3

The options vested 100% on December 31, 2025.

Footnote F4

The shares were sold in multiple transactions at prices ranging from $5.00 to $5.12. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .